Prostate Cancer Survival Analysis of 872 Patients in Southern Iran: A Retrospective Cohort Study

Background: Prostate cancer remains one of the most common and lethal cancers among men worldwide. This study aimed to investigate the characteristics, prognostic factors, and outcomes of patients with prostate cancer who were treated and followed up in Shiraz, southern Iran over the past 12 years.M...

Full description

Bibliographic Details
Main Authors: Mahsa Sepahvand, Alireza Salehi, Ali Omidvari, Shapour Omidvari, Mohammad Mohammadianpanah
Format: Article
Language:English
Published: Shiraz University of Medical Sciences 2023-10-01
Series:Middle East Journal of Cancer
Subjects:
Online Access:https://mejc.sums.ac.ir/article_49207_9f167bb4f52dfb73e960bb6dda3b78e5.pdf
_version_ 1797663401555525632
author Mahsa Sepahvand
Alireza Salehi
Ali Omidvari
Shapour Omidvari
Mohammad Mohammadianpanah
author_facet Mahsa Sepahvand
Alireza Salehi
Ali Omidvari
Shapour Omidvari
Mohammad Mohammadianpanah
author_sort Mahsa Sepahvand
collection DOAJ
description Background: Prostate cancer remains one of the most common and lethal cancers among men worldwide. This study aimed to investigate the characteristics, prognostic factors, and outcomes of patients with prostate cancer who were treated and followed up in Shiraz, southern Iran over the past 12 years.Method: This retrospective medical chart review was performed on 872 patients with prostate cancer who were treated and followed up in the Radiation Oncology Department of Shiraz University of Medical Sciences. The survival analysis was conducted for the patients, and the receiver operating characteristic (ROC) curve analysis was performed for the prostate-specific antigen (PSA) level.Results: The median age of the patients at presentation was 69 years (range 35-91 years). In terms of local treatments, 28% of the patients underwent prostatectomy, and 23% were treated with transurethral resection of the prostate. The remaining 49% of patients were treated with non-surgical therapies. Patients between 55 and 75 years had the longest survival duration. The shortest survival was observed in the third Gleason group and those over 75 years old, while the first Gleason group and patients younger than 55 years had the longest survival duration. Hypoalbuminemia had no effect on the survival duration. A PSA level of 33.8 ng/dl was the most suitable cutoff point to predict bone metastasis, and patients with a PSA level of more than 33.8 ng/dl had significantly less survival duration than the others.Conclusion: More aggressive treatment and shorter follow-up intervals are recommended for patients with an initial PSA level of more than 33.8 and those younger than 55 years old.
first_indexed 2024-03-11T19:14:01Z
format Article
id doaj.art-4bfbf830404f4453b692f96fc6e04cb7
institution Directory Open Access Journal
issn 2008-6709
2008-6687
language English
last_indexed 2024-03-11T19:14:01Z
publishDate 2023-10-01
publisher Shiraz University of Medical Sciences
record_format Article
series Middle East Journal of Cancer
spelling doaj.art-4bfbf830404f4453b692f96fc6e04cb72023-10-09T09:02:56ZengShiraz University of Medical SciencesMiddle East Journal of Cancer2008-67092008-66872023-10-0114457057710.30476/mejc.2023.95281.176349207Prostate Cancer Survival Analysis of 872 Patients in Southern Iran: A Retrospective Cohort StudyMahsa Sepahvand0Alireza Salehi1Ali Omidvari2Shapour Omidvari3Mohammad Mohammadianpanah4MPH Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IranMPH Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IranMPH Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IranBreast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, IranColorectal Research Center, Shiraz University of Medical Sciences, Shiraz, IranBackground: Prostate cancer remains one of the most common and lethal cancers among men worldwide. This study aimed to investigate the characteristics, prognostic factors, and outcomes of patients with prostate cancer who were treated and followed up in Shiraz, southern Iran over the past 12 years.Method: This retrospective medical chart review was performed on 872 patients with prostate cancer who were treated and followed up in the Radiation Oncology Department of Shiraz University of Medical Sciences. The survival analysis was conducted for the patients, and the receiver operating characteristic (ROC) curve analysis was performed for the prostate-specific antigen (PSA) level.Results: The median age of the patients at presentation was 69 years (range 35-91 years). In terms of local treatments, 28% of the patients underwent prostatectomy, and 23% were treated with transurethral resection of the prostate. The remaining 49% of patients were treated with non-surgical therapies. Patients between 55 and 75 years had the longest survival duration. The shortest survival was observed in the third Gleason group and those over 75 years old, while the first Gleason group and patients younger than 55 years had the longest survival duration. Hypoalbuminemia had no effect on the survival duration. A PSA level of 33.8 ng/dl was the most suitable cutoff point to predict bone metastasis, and patients with a PSA level of more than 33.8 ng/dl had significantly less survival duration than the others.Conclusion: More aggressive treatment and shorter follow-up intervals are recommended for patients with an initial PSA level of more than 33.8 and those younger than 55 years old.https://mejc.sums.ac.ir/article_49207_9f167bb4f52dfb73e960bb6dda3b78e5.pdfprostatic neoplasmssurvival analysisprostate-specific antigenprognosisroc curve
spellingShingle Mahsa Sepahvand
Alireza Salehi
Ali Omidvari
Shapour Omidvari
Mohammad Mohammadianpanah
Prostate Cancer Survival Analysis of 872 Patients in Southern Iran: A Retrospective Cohort Study
Middle East Journal of Cancer
prostatic neoplasms
survival analysis
prostate-specific antigen
prognosis
roc curve
title Prostate Cancer Survival Analysis of 872 Patients in Southern Iran: A Retrospective Cohort Study
title_full Prostate Cancer Survival Analysis of 872 Patients in Southern Iran: A Retrospective Cohort Study
title_fullStr Prostate Cancer Survival Analysis of 872 Patients in Southern Iran: A Retrospective Cohort Study
title_full_unstemmed Prostate Cancer Survival Analysis of 872 Patients in Southern Iran: A Retrospective Cohort Study
title_short Prostate Cancer Survival Analysis of 872 Patients in Southern Iran: A Retrospective Cohort Study
title_sort prostate cancer survival analysis of 872 patients in southern iran a retrospective cohort study
topic prostatic neoplasms
survival analysis
prostate-specific antigen
prognosis
roc curve
url https://mejc.sums.ac.ir/article_49207_9f167bb4f52dfb73e960bb6dda3b78e5.pdf
work_keys_str_mv AT mahsasepahvand prostatecancersurvivalanalysisof872patientsinsoutherniranaretrospectivecohortstudy
AT alirezasalehi prostatecancersurvivalanalysisof872patientsinsoutherniranaretrospectivecohortstudy
AT aliomidvari prostatecancersurvivalanalysisof872patientsinsoutherniranaretrospectivecohortstudy
AT shapouromidvari prostatecancersurvivalanalysisof872patientsinsoutherniranaretrospectivecohortstudy
AT mohammadmohammadianpanah prostatecancersurvivalanalysisof872patientsinsoutherniranaretrospectivecohortstudy